Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Dec:9:23247096211056768.
doi: 10.1177/23247096211056768.

Dural Follicular Lymphoma: Case Report and Literature Review

Affiliations
Review

Dural Follicular Lymphoma: Case Report and Literature Review

Ellery Altshuler et al. J Investig Med High Impact Case Rep. 2021 Jan-Dec.

Abstract

Follicular lymphoma (FL) usually has an indolent course and presents with painless, waxing and waning lymphadenopathy in the absence of systemic symptoms. It is uncommon for FL to present outside of lymph nodes, although it can develop in the gastrointestinal tract, skin, thyroid, and testes. Central nervous system (CNS) involvement in FL is rare. Most CNS lymphomas are diffuse large B-cell lymphoma, although Burkitt lymphoma, lymphoblastic lymphoma, and peripheral T-cell lymphoma are also observed. These tumors usually involve white matter but may also involve gray matter. Lymphomas of the dura are very uncommon and are usually mucosa-associated lymphoid tissue lymphomas. Here, we present a case of FL of the dura arising in a 62-year-old woman that was responsive to chemotherapy. According to a literature review, there have been 15 previously reported cases of FL of the dura. Dural FL has been most frequently treated with radiation and chemotherapy. Patients were still alive in all cases in which follow-up was reported. Although the sample size is small, these data suggest that dural FL, like other forms of FL, is an indolent disease that is associated with prolonged survival despite usually being incurable.

Keywords: central nervous system; dural follicular lymphoma; primary lymphoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Coronal (left) and axial (right) magnetic resonance images demonstrating a 2.3 × 1.0 × 2.7 cm dural-based mass (yellow arrows) in the left frontoparietal region with associated thickening and enhancement of the adjacent dura. There is an extracranial component to the mass in the adjacent soft tissues without visible abnormalities of the bone. In addition, there are linear extension into the gyri of the adjacent brain parenchyma with an associated focal area of subcortical edema in the lateral aspect of the postcentral gyrus.
Figure 2.
Figure 2.
(A) The dura demonstrates infiltration of fibrous tissue by a vaguely nodular lymphocytic infiltrate (hematoxylin and eosin, 40× magnification). (B) Closer inspection of 1 of the nodular areas reveals the infiltrate to consist of a mixture of small lymphocytes with cleaved nuclei (centrocytes) and large lymphocytes with multiple nucleoli (centroblasts) (hematoxylin and eosin, 400× magnification).
Figure 3.
Figure 3.
(A) Lymphocytes express CD20, consistent with B cells (CD20 immunohistochemical stain, 200× magnification). (B) CD21 highlights retained follicular dendritic cell meshworks (CD21 immunohistochemical stain, 200× magnification). B cells show aberrant co-expression of (C) Bcl-2 and (D) Bcl-6 (Bcl-2 and Bcl-6 immunohistochemical stains, 200× magnification). The overall morphological and immunophenotypic findings support the diagnosis of follicular lymphoma.

References

    1. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015;15(5):531-544. doi:10.1586/14737140.2015.1023712. - DOI - PMC - PubMed
    1. Batlevi CL, Sha F, Alperovich A, et al.. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74. - PMC - PubMed
    1. Junlén HR, Peterson S, Kimby E, et al.. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668-676. doi:10.1038/leu.2014.251. - DOI - PubMed
    1. Raghavan SC, Swanson PC, Wu X, et al.. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature. 2004;428(6978):88. doi:10.1038/nature02355. - DOI - PubMed
    1. Martin AR, Weisenburger DD, Chan WC, et al.. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995;85(12):3671-3678. doi:10.1182/blood.V85.12.3671. - DOI - PubMed

MeSH terms

LinkOut - more resources